Prognostic significance of heart rate turbulence parameters in patients with chronic heart failure

De-Chun Yin1, Zhao-Jun Wang1, Shuai Guo1, Hong-Yu Xie1, Lin Sun1, Wei Feng1, Wei Qiu1 and Xiu-Fen Qu1,2*

Abstract

Background: This study is aimed to evaluate the clinical significance of heart rate turbulence (HRT) parameters in predicting the prognosis in patients with chronic heart failure (CHF).

Methods: From June 2011 to December 2012, a total of 104 CHF patients and 30 healthy controls were enrolled in this study. We obtained a 24-hour Holter ECG recording to assess the HRT parameters, included turbulence onset (TO), turbulence slope (TS), standard deviation of N-N intervals (SDNN), and resting heart rate (RHR). The relationships between HRT parameters and the prognosis of CHF patients were determined.

Results: The assessment follow-up period lasted until January 31, 2013. The overall mortality of CHF patients was 9.6% (10/104). Our results revealed that CHF patients had higher levels of TO than those of healthy subjects, but the TS levels of CHF patients were lower than that of the control group. CHF patients with NYHA grade IV had higher HRT1/2 rate than those with NYHA grade II/III. There were statistical differences in TS, LVEF, SDNN and RHR between the non-deteriorating group and the non-survivor group. Significant differences in TS among the three groups were also found. Furthermore, CHF patients in the non-survivor group had lower levels of TS than those in the deteriorating group. Correlation analyses indicated that TO negatively correlates with SDNN, while TS positively correlated with SDNN and left ventricular ejection fraction (LVEF). We also observed negative correlations between TS and left ventricular end-diastolic cavity dimension (LVEDD), RHR, homocysteine (Hcy) and C-reactive protein (CRP). Multivariate Cox regression analysis further confirmed that LVEF (≤30%), HRT2, SDNN and RHR were independent risk factors which can indicate poor prognosis in CHF patients.

Conclusions: Our findings indicate that HRT may have good clinical predictive value in patients with CHF. Thus, quantifying HRT parameters could be a useful tool for predicting mortality in CHF patients.

Keywords: Heart rate turbulence, Chronic heart failure, Prognosis

Background

Chronic heart failure (CHF), one of the most common forms of heart failure, is a pathophysiological state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate necessary to deliver nutrients to metabolizing tissues [1]. Despite advances in medical and surgical treatments, mortality in CHF patients remains high, and the five-year mortality rate in CHF patients averages 50%, whereas in the end-stage CHF, it may reach 75%; and the sudden death rate accounts for 30 ~ 50% of total mortality [2,3]. Recent studies have confirmed that the prognosis of CHF is uniformly poor, and the accuracy of diagnosis through clinical means alone is often inadequate, particularly in elderly obese people [4,5]. Currently, several studies have indicated that various indices or electrocardiographically derived parameters have been commonly used and tested as prognostic predictors for CHF [6,7].

Clinically, the currently accepted prognostic indicators for CHF mainly consist of heart rate variability (HRV) and LVEF, which may both have some limitations to their own extents [8]. HRV, as one of the oldest Holter-derived risk stratification parameters, is an established parameter for analyzing the performance of autonomic regulation in the sinus node [9]. Nevertheless, it is only mildly inclined to a series of physiological reflexes caused...
The diagnostic criteria for CHF as specified by the 1995 World Health Organization/International Society and Federation Cardiology (WHO/ISFC); [19] (2) there must exist evidence for CHF, such as dyspnea, left/right heart failure, cardiac dilatation and left ventricular ejection fraction (LVEF) < 50%; (3) each patient presented with sinus rhythm also had >5 ventricular premature beats (VPBs) measured; (4) patients diagnosed with CHF were graded II ~ IV according to the NYHA classification [20]. Patients were excluded based on the following criteria: (1) patients had chronic or persistent atrial fibrillation, an implanted permanent pacemaker or cardiac resynchronization therapy; (2) patients were in the acute phase of congestive heart failure or MI; (4) inability to perform a HRT determination or reliable data analysis; (5) patients had hypertrophic cardiomyopathy, myocarditis, diabetes, heart disease, pulmonary heart disease or history of myocardial infarction within 2 months; (6) patients had liver, kidney and other serious organs diseases; (7) patients took antiarrhythmia drugs other than β-blocker; (8) there existed too much interference in dynamic ECG.

In our present study, 104 CHF patients (72 males and 32 females) were enrolled with a mean age of 61.0 ± 10.0 years (range, 39 ~ 84 years). According to the NYHA classification, these patients were divided into grade II (16 males and 7 females), grade III (20 males and 27 females) and grade IV (27 males and 7 females) groups. There were 37 patients (28 males and 9 females) with ischemic heart disease and 67 patients (35 males and 32 females) with nonischemic heart disease. In addition, 30 healthy controls (21 males and 9 females) with a mean age of 58.0 ± 9.0 years (range, 40 ~ 83 years) were enrolled in the control group after detailed medical examination, which includes medical history taking, physical examination, chest X-ray, echocardiography, Holter monitoring and blood biochemical examination.

Holter recording and evaluation of HRT parameters
All patients were managed under a uniform and standard assay method. HRT of CHF patients were quantified by TO and TS acquired through the 24-hour 3-lead Holter digital recordings (Syneflash recorder; ELA Medical, Le Plessis Robinson, France) according to a previously published method [13]. HRT was analyzed using the HRT Version 0.6 ~ 0.1 software program (Munich Germany). TO is the difference between the mean of the first two RR intervals after a VPB and the last two RR intervals before the VPB. Positive values for TO indicate deceleration, whereas negative values indicate acceleration of the sinus rhythm. TS, the maximum positive value of the slope of a regression line assessed over any sequence of five subsequent sinus-rhythm RR intervals within the first 20 sinus rhythm intervals after a VPB, are expressed in millisecond per interval RR (ms/RR). \( TO > 0\% \), \( TS < 0\% = 2.5 \) ms/RR were considered abnormal by the external environment and in vitro stimulation, and cannot reflect the instantaneous malignant arrhythmias. [10]. As for LVEF, it primarily reflects mechanical LV systolic function, however, in the clinical there were a large number of patients suffering from a high risk of sudden death who only detected a mild to moderate left ventricular function with CHF [11,12]. Therefore, it might be essential to actively explore other useful and valid predictors for CHF suffers since the existing clinical techniques may be inappropriate to applied as a biomarker of high risk of sudden death in CHF.

Heart rate turbulence (HRT), modulated by the baroreceptor reflex, is a physiological biphasic response of the sinus node to premature ventricular contractions, which involves a short initial acceleration followed by a deceleration of the sinus rhythm due to the baroreflex. [13] There are two numeric descriptors that are usually employed to quantify HRT parameter: one is the turbulence onset (TO), which reflects the initial acceleration of heart rate after a ventricular premature beat (VPB); the other is the turbulence slope (TS), which is used to describe subsequent deceleration of heart rate following a ventricular premature beat [13,14]. Previous studies have shown that HRT assessment might be an important parameter in risk stratification after MI and has been suggested that it could be used as a measure of autonomic dysfunction [15,16]. Clinically, HRT can facilitate the predictive accuracy of nonsustained ventricular tachycardia (NSVT) in identifying patients at risk for serious arrhythmic events and in patients with left ventricular (LV) dysfunction [17]. Recent studies have proved more evidence that HRT parameters may be regarded as surrogate measures for baroreflex sensitivity in clinical and prognostic evaluation in patients with CHF [13,18]. In this study, we evaluated the clinical significance of HRT parameters in predicting prognosis in patients with CHF and determine whether HRT parameters could be considered as markers of the development and progression of CHF.

Methods
Ethics statement
The Ethics Committee of the First Affiliated Hospital of Harbin Medical University approved the study design. All patients gave informed consent in written to undergo diagnostic and therapeutic procedure at the time of hospitalization.

Study design and subjects
The study was performed in patients diagnosed of CHF when admitted to the First Affiliated Hospital of Harbin Medical University from June 2011 to December 2012. Patients enrolled in this study must satisfy all of the following criteria: (1) all patients in the study had to meet the diagnostic criteria for CHF as specified by the 1995 World Health Organization/International Society and Federation Cardiology (WHO/ISFC); [19] (2) there must exist evidence for CHF, such as dyspnea, left/right heart failure, cardiac dilatation and left ventricular ejection fraction (LVEF) < 50%; (3) each patient presented with sinus rhythm also had >5 ventricular premature beats (VPBs) measured; (4) patients diagnosed with CHF were graded II ~ IV according to the NYHA classification [20]. Patients were excluded based on the following criteria: (1) patients had chronic or persistent atrial fibrillation, an implanted permanent pacemaker or cardiac resynchronization therapy; (2) patients were in the acute phase of congestive heart failure or MI; (4) inability to perform a HRT determination or reliable data analysis; (5) patients had hypertrophic cardiomyopathy, myocarditis, diabetes, heart disease, pulmonary heart disease or history of myocardial infarction within 2 months; (6) patients had liver, kidney and other serious organs diseases; (7) patients took antiarrhythmia drugs other than β-blocker; (8) there existed too much interference in dynamic ECG.

Holter recording and evaluation of HRT parameters
All patients were managed under a uniform and standard assay method. HRT of CHF patients were quantified by TO and TS acquired through the 24-hour 3-lead Holter digital recordings (Syneflash recorder; ELA Medical, Le Plessis Robinson, France) according to a previously published method [13]. HRT was analyzed using the HRT Version 0.6 ~ 0.1 software program (Munich Germany). TO is the difference between the mean of the first two RR intervals after a VPB and the last two RR intervals before the VPB. Positive values for TO indicate deceleration, whereas negative values indicate acceleration of the sinus rhythm. TS, the maximum positive value of the slope of a regression line assessed over any sequence of five subsequent sinus-rhythm RR intervals within the first 20 sinus rhythm intervals after a VPB, are expressed in millisecond per interval RR (ms/RR). \( TO > 0\% \), \( TS < 0\% = 2.5 \) ms/RR were considered abnormal...
[18]. Based on the previous study, patients in our current study were stratified into three groups: HRT$_0$ group with TO < 0 and TS > 2.5 ms/normal-to-normal interval (both factors normal); HRT$_1$ group with either TO ≥ 0 or TS = 2.5 ms/RR (1 factor abnormal); HRT$_2$ group with TO ≥ 0 and TS ≤ 2.5 ms/RR (both factors abnormal) [18]. For the entire study population, time-domain measurements of heart rate variability (HRV), including mean N-N intervals, standard deviation of N-N intervals (SDNN), and resting heart rate (RHR), left ventricular end-diastolic dimension (LVEDD) were calculated from the 24-hour Holter ECG recording. The RHR was measured after 5 minutes rest while seated in a quiet room [21].

Two-dimensional and Doppler echocardiographic examinations were performed with a HP5500 ultrasound system (Hewlett Packard, Andover, Mass, USA). In the parasternal long-axis view, M-mode echocardiograms were made of left ventricle from the left hemithorax in short-axis.

Follow-up
The median duration of the entire study follow-up was 10.5 ± 8.3 months (range, 6 ~ 18 months). All events recorded in the study were adjudicated blindly by an ad-hoc committee on the basis of pre-agreed definitions and procedures. Follow-up information was collected for all patients through outpatient service and phone calls. The end point was prospectively defined as the composite of heart failure and cardiac mortality.

The assessment follow-up period lasted until January 31, 2013. Finally, the overall mortality of CHF patients was 9.6% (10/104). There were 32 CHF patients (26 males and 6 females) exhibiting a deterioration of cardiac function and 62 patients showing no significant deterioration.

Statistical analysis
Data were expressed as mean ± standard deviation (mean ± SD) unless otherwise specified and qualitative data are presented as percentages. Comparative analyses between the groups were performed with the Student’s t-test for continuous variables and χ$^2$ or Fisher’s exact test for dichotomous parameters. Correlation between autonomic markers was assessed with Spearman correlation coefficient. Survival curves were estimated with the Kaplan-Meier method and compared by the log-rank test. Independent predictors of death were identified with multivariate Cox proportional hazards model and expressed as hazard ratio (HR) with 95% confidence interval (CI). A P value of less than 0.10 was considered statistically significant and all tests were two-sided. All analyses were performed using the SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA).

Results
Comparison of heart rate turbulence
The differences in HRT between CHF patients and healthy subjects are summarized in Table 1. Our results revealed that CHF patients exhibited a significant reduction in HRT levels. CHF patients had higher levels of TO than those of healthy subjects (0.48 ± 1.58% vs. -1.73 ± 2.58%, P < 0.001), but the TS levels of CHF patients were lower than that of the control group (1.88 ± 1.99 vs. 4.41 ± 1.71 ms/RR, P < 0.001). There was a significant difference in the rate of HRT$_{1/2}$ between CHF patients and healthy controls (89/104 vs. 22/30, P < 0.001). Furthermore, CHF patients with NYHA grade IV had higher HRT$_{1/2}$ rate than those with NYHA grade II/III (P = 0.013, 0.051, respectively) (Figure 1).

Relevance factors of HRT
Correlation analyses indicated that TO negatively correlated with SDNN (r = -0.316, P < 0.001), but no associations were found between TO and other factors (all P > 0.05). TS positively correlated with SDNN (r = 0.270, P < 0.001) and LVEF (r = 0.365, P < 0.001). However, there were negative associations between TS and LVEDD (r = -0.313, P < 0.001), RHR (r = -0.299, P = 0.001), Hcy (r = -0.198, P < 0.001) and CRP (r = -0.278, P < 0.001). We also observed no correlations with TS to age and TC levels (both P > 0.05). Correlations of TO and TS with relevance factors are shown in Table 2 and Figure 2.

Comparison of CHF patients with different prognosis
Our results suggested that there were statistical differences in TS, LVEF, SDNN and RHR between the non-deteriorating group and the non-survivor group (all P < 0.05, as shown in Table 3). We observed a significant difference in TS among the three groups (all P < 0.05). Furthermore, CHF patients in the non-survivor group had lower levels of TS than those in the deteriorating group (P < 0.001).

Survival analysis
Univariate survival analysis demonstrated that age (≥65), LVEF (≤30%), SDNN (≤100 ms), RHR (≥75 bpm), HRT$_1$
and HRT2 were associated with poor prognosis in CHF patients (all $P < 0.05$) (Table 4). Multivariate Cox regression analysis indicated that LVEF ($\leq 30\%$), HRT2, SDNN and RHR were independent risk factors for poor prognosis in CHF patients (all $P < 0.05$) (Table 5). Among these risk factors, HRT2 was the strongest predictor of CHF with a high hazard risk of 5.12. The survival curve also showed that the survival rate of CHF patients with HRT0 and HRT1 were higher than those with HRT2 (all $P < 0.05$) (Figure 3).

**Discussion**

HRT is a baroreflex-mediated biphasic reaction of heart rate in response to premature ventricular beats [22]. Generally, abnormal HRT is widely accepted to be indicative of potential autonomic dysfunction or impaired baroreflex sensitivity in patients due to variety of disorders; it may also reflect changes in autonomic nervous system induced by different therapeutic modalities such as drugs, revascularization, or cardiac resynchronization therapy [15,23]. More importantly, impaired HRT has been demonstrated in identifying patients at high risk for all-cause mortality and sudden death, particularly in post-infarction and congestive heart failure patients [24]. Notably, HRT have a higher specificity and sensitivity as compared to some other detection methods since it is a bi-physiological response of the interaction between sinus and ventricular contraction that reflect the sensitive outcome of extremely weak endogenous stimuli triggering reflex regulation [25,26]. In recent decades, increasing number of clinical applications in HRT have gained global popularity as well as considerable successes, and it has been previously described as an independent predictor of mortality in patients with cardiovascular diseases [27,28].

Generally, HRT is described as the acceleration and subsequent deceleration of sinus rate [29]. Abnormal HRT has a well-established role in the stratification of post-infarction and heart failure in patients [30]. However, current emphasis on the medical application of HRT is far from perfect, and its function has not been fully assessed. In this study, we evaluated the relationships between HRT parameters and prognosis in CHF patients to explore the predictive values of HRT parameters in the development and progression of CHF. This study revealed that CHF patients exhibited a significant reduction in HRT levels with higher TO levels and lower TS levels than the healthy subjects, suggesting that the HRT levels may be closely related to the development and progression of CHF. Although the exact reasons for HRT reduction in patients with CHF are not fully understood, a potential explanation could be that CHF patients may suffer from myocardial deformation or damages in the terminal receptors, and abnormal sympathetic and vagal afferent stimulation, which may lead to dullness of baroreflex, cause decreased HRT or disappearance of HRT after VPBs in patients with organic heart disease [31]. Sredniawa et al. demonstrated that CHF patients were associated with more abnormal average values of HRT parameters, as a marker of the autonomic

**Table 2 Correlations of TO and TS with relevance factors**

| Factors   | TO     | P      | TS     | P      |
|----------|--------|--------|--------|--------|
| Age      | 0.760  | 0.401  | −0.600 | 0.505  |
| LVEDD    | 0.152  | 0.090  | −0.313 | <0.001 |
| LVEF     | −0.268 | 0.060  | 0.365  | 0.001  |
| SDNN     | −0.316 | <0.001 | 0.270  | 0.020  |
| RHR      | 0.211  | 0.180  | −0.299 | 0.010  |
| TC       | 0.359  | 0.301  | −0.640 | 0.305  |
| Hcy      | 0.314  | 0.062  | −0.198 | <0.001 |
| CRP      | 0.218  | 0.052  | −0.278 | <0.001 |

TO, turbulence onset; TS, turbulence slope; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; SDNN, standard deviation of N-N intervals; RHR, resting heart rate; TC, total cholesterol; Hcy, homocysteine; CRP, C-reaction protein.
regulation in the heart, might play important roles in the progression toward end-stage heart failure or all-cause mortality of CHF patients [18]. Analysis of HRT is an easy and innocuous way to assess the parasympathetic nervous system, and it can be used as a prognostic marker both in ischemic heart disease and heart failure; in some cases, it even has a better correlation than LVEF [32]. We also found a significant difference in HRT1/2 rate between CHF

![Image of Figure 2: Correlations of HRT parameters (TO and TS) with SDNN, RHR and LVEDD.](image)

### Table 3 Comparison of CHF patients with different prognosis

| Factors     | Non-deteriorating group (n = 62) | Deteriorating group (n = 32) | Non-survivor group (n = 10) |
|-------------|----------------------------------|-----------------------------|----------------------------|
| Age         | 64.78 ± 11.92                    | 60.63 ± 10.25               | 60.12 ± 10.34              |
| TO          | 0.33 ± 1.64                      | 0.23 ± 1.53                 | 0.95 ± 1.63                |
| TS          | 2.50 ± 2.61                      | 2.15 ± 1.82*                | 0.87 ± 1.33*               |
| LVEDD       | 44.58 ± 10.12                    | 41.24 ± 7.24                | 26.82 ± 8.86*              |
| LVEF        | 56.15 ± 7.17                     | 53.31 ± 9.01                | 61.01 ± 9.40               |
| SDNN        | 102.88 ± 36.98                   | 97.28 ± 34.88               | 95.57 ± 31.66*            |
| RHR         | 76.65 ± 15.23                    | 83.48 ± 12.76               | 89.58 ± 14.07*            |
| TC          | 4.56 ± 4.36                      | 4.16 ± 0.16                 | 3.16 ± 0.62               |
| Hcy         | 8.59 ± 2.06                      | 14.55 ± 4.11               | 16.95 ± 6.30              |
| CRP         | 7.71 ± 1.22                      | 11.84 ± 2.96                | 12.67 ± 5.67              |

*P < 0.05 compared with the non-deteriorating group; **P < 0.05 compared with the non-survivor group.

### Table 4 Univariate survival analysis of HRT parameters with prognosis of CHF patients

| Factors     | HR (95% CI) | P value |
|-------------|-------------|---------|
| Age         | 3.91 (1.03, 19.56) | 0.048   |
| HRT0        | 1.34 (0.50, 3.38)  | 0.648   |
| HRT1        | 3.78 (1.86, 7.01)  | 0.010   |
| HRT2        | 5.40 (2.65, 25.48) | 0.015   |
| LVEF        | 4.96 (1.83, 17.20) | 0.020   |
| LVEDD       | 2.70 (1.08, 7.36)  | 0.038   |
| SDNN        | 3.95 (1.11, 14.02) | 0.034   |
| RHR         | 4.04 (1.39, 20.95) | 0.015   |

HRT, heart rate turbulence; CHF, chronic heart failure; HR, hazard risk; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; SDNN, standard deviation of N-N intervals; RHR, resting heart rate.
patients and healthy controls. Furthermore, CHF patients with NYHA grade IV had a higher positive rate of HRT1/2 than those with NYHA grade II/III, revealing that HRT was correlated with the severity of CHF. The observation of more depressed HRT in patients with advanced NYHA functional class is also consistent with previous reports and studies [33]. In addition, our study also found statistical differences in TS, LVEF, SDNN and RHR between the non-deteriorating group and the non-survivor group; significant differences in TS among the three groups were also observed. Moreover, correlation analyses indicated that both the TS and TO were significantly correlated with SDNN and that only TS was significantly correlated with LVEF. These findings revealed that TS could be considered as a stronger predictor of hospitalization for worsening heart failure and death in CHF patients than LVEF, SDNN and RHR. The mechanisms of the decreased TS in CHF patients are not clear; it is likely that the TS is more susceptible to CHF events because it correlates with both the left ventricular function and the cardiac autonomic status [34]. Consistent with our results, a previous study suggested that the TS appears to be a more suitable prognostic marker for CHF death and hospitalization than LVEF and SDNN, which further confirmed that HRT serves great predictive value in the prognosis of CHF [35].

Univariate survival analysis demonstrated that age (≥65), LVEF (≤30%), SDNN (≤100 ms), RHR (≥75 bpm), HRT1 and HRT2 were associated with poor prognosis of CHF patients. Multivariate Cox regression analysis indicated that LVEF (≤30%), HRT2, SDNN and RHR were independent risk factors for poor prognosis of CHF patients. Among these risk factors, HRT2 (the combination of abnormal TO and TS) was the strongest predictor of CHF with a high hazard risk of 5.12 after CHF and remained highly significant after adjustment for LVEF and other clinical risk factors. The combination of abnormal TO and TS may result in tachycardia which would cause decreased heart efficiency in increased myocardial oxygen consumption, decreased myocardial perfusion during myocardial relaxation and diastolic, thereby leading to myocardial injury and aggravating or worsening heart failure [36]. Nevertheless, some limitations of this study should be acknowledged. Firstly, a lack of image analysis software to automatically identify and analyze the matched VPBs, as well as HRT, limited the accuracy in the prognostic significance of HRT in CHF patients. Secondly, HRT level is easily affected by various factors, therefore certain limitations still remain in the sensitivity, specificity and positive predictive value of HRT in CHF patients.

### Table 5 Multivariate cox regression analysis of HRT parameters with prognosis of CHF patients

|        | HR (95% CI) | P value |
|--------|-------------|---------|
| HRT1   | 5.12 (1.53, 16.37) | 0.022   |
| HRT2   | 4.68 (1.54, 16.78) | 0.030   |
| LVEF   | 1.37 (0.84, 2.13)  | 0.123   |
| LVEDD  | 3.69 (1.32, 11.46) | 0.046   |
| SDNN   | 3.18 (1.69, 17.43) | 0.034   |
| RHR    | 1.84 (0.77, 2.46)  | 0.152   |

HRT, heart rate turbulence; CHF, chronic heart failure; HR, hazard risk; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; SDNN, standard deviation of N-N intervals; RHR, resting heart rate.

Figure 3 Survival curve for the survival rate of CHF patients with HRT0, HRT1 and HRT2.
Thirdly, due to the short follow-up time and the relatively small sample size, the correlation between HRT and CHF requires further verification.

Conclusions
Our findings indicated that HRT may have good clinical predictive values in patients with CHF. Thus, quantifying HRT parameters could be useful tool in predicting mortality in CHF patients. However, due to the limitations mentioned above, further detailed studies with larger sample size and longer follow-up periods are still required to confirm our results.

Competing interests
The authors have declared no competing interests among themselves.

Authors’ contribution
YDC carried out the experiments and drafted the manuscript. WSJ, GS and FW analyzed the data. XHY, SL and QW contributed the material and the analysis tools. YDC and QXF participated in the design of the study and performed the statistical analysis. QXF conceived the study, and participated in its design and coordination and helped draft the manuscript. All authors read and approved the final manuscript.

Acknowledgments
This work was supported by the Department of Health Project of Heilongjiang Province (2013025). We would also like to thank our colleagues at the Department of Cardiology, the First Affiliated Hospital of Harbin Medical University.

Received: 19 December 2013 Accepted: 3 April 2014
Published: 13 April 2014

References
1. Melillo P, Fusco R, Sansone M, Bracale M, Pecchia L: Discrimination power of long-term heart rate variability measures for chronic heart failure detection. Med Biol Eng Comput 2011, 49:67–74.
2. Bui AL, Horwich TB, Fonarow GC: Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011, 8:30–41.
3. Ramani GV, Uber PA, Mehra MR: Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc 2010, 85:180–195.
4. Barrios V, Escobar C, De La Sierra A, Listeri J, Gonzalez-Segura D: Detection of unrecognized clinical heart failure in elderly hypertensive women attended in primary care setting. Blood Press 2010, 19(5):301–307.
5. Bokurt B, Mann DL, McFetridge-Durdle JA: Inflammation and heart failure. Heart Fail Rev 2010, 15:331–341.
6. Parissis JT, Iliodromiti I, Rafoul-Stiengou P, Mebazaa A, Delgado J, Farmakis D, Vlachos D, Paranos E, Perivolaris I, Anastasiou-Nana M, Follath F: Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction. Am J Cardiol 2011, 107:99–84.
7. Routledge FS, Campbell TS, McFetridge-Durdle JA, Bacon SL: Improvements in heart rate variability with exercise therapy. Can J Cardiol 2010, 26:303–312.
8. Smilde TD, van Veldhuisen DJ, van den Berg MP: Prognostic value of heart rate variability and ventricular arrhythmias during 13-year follow-up in patients with mild to moderate heart failure. Clin Res Cardiol 2009, 98:233–239.
9. Thayer JF, Yarnamoto SS, Brosschot JF: The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol 2010, 141:122–131.
10. Xhyheri B, Manfrini O, Mazzolini M, Pizzi C, Bugiardini R: Heart rate variability today. Prog Cardiovasc Dis 2012, 55(4):321–331.
11. Clavel MA, Dumontel JG, Capoulade R, Mathieu P, Senechal M, Pibarot P: Outcome of patients with aortic stenosis, small valve area, and low-flow, low-gradient despite preserved left ventricular ejection fraction. J Am Coll Cardiol 2012, 60(1):1259–1267.
12. Pellicori P, Kalvikavaka-Bennett A, Khaleva O, Carubelli V, Costanzo P, Castiello T, Wong K, Zhang J, Cleland JG, Clark AJ: Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? Int J Cardiac Imaging 2014, 30(1):69–79.
13. La Rovere MT, Maestri R, Pinna GD, Sleight P, Febo O: Clinical and haemodynamic correlates of heart rate turbulence as a non-invasive index of baroreflex sensitivity in chronic heart failure. Clin Sci (Lond) 2011, 121(6):279–284.
14. DAddio G, Cesarelli M, Corbi G, Romano M, Furgi G, Ferrara N, Rengo F: Reproducibility of heart rate turbulence indexes in heart failure patients. Conf Proc IEEE Eng Med Biol Soc 2010, 2010:2573–2576.
15. Biais P, Ciuryzynski M, Gilska-Wiolechowska M, Szweczyk A, Kozaczak D, Kalinska-Bienas A, Glinski W, Pruszczynski P: Heart rate turbulence assessment in systemic sclerosis: the role for the detection of cardiac autonomic nervous system dysfunction. Rheumatology (Oxford) 2010, 49(2):355–360.
16. Szymonowkla K, Piatkowski A, Nowicka A, Michalski M, Dankowski R, Kandziora B, Biegalski W, Wierzchowiecki M, Poprawski K: Clinical significance of heart rate turbulence assessment in patients with chronic heart failure. Kardiol Pol 2008, 66(1):1289–1295.
17. Mivo Y, Yoshino H, Hoshida K, Miyakoshi M, Tsukada T, Yusu S, Ikeeda T: Risk stratification for serious arrhythmic events using nonsustained ventricular tachycardia and heart rate turbulence detected by 24-hour holter electrocardiograms in patients with left ventricular dysfunction. Ann Noninvasive Electrocardiol 2012, 17(3):260–267.
18. Sredniawa B, Cebula S, Kowalczyk J, Batchvarov VN, Musialik-Lydka A, Slivinska A, Wozniak A, Zakliczynski M, Zembala M, Kalarus Z: Heart rate turbulence for prediction of heart transplantation and mortality in chronic heart failure. Ann Noninvasive Electrocardiol 2010, 15(3):230–237.
19. Parkewut S, Hufnagel G, Eckhardt H, Herrmann H, Uttech S, Maisch B: Cardiotoxic DNA viruses and bacteria in the pathogenesis of dilated cardiomyopathy with or without inflammation. Med Klin (Munich) 1998, 93(4):223–228.
20. Shi Z, Gao CY, Liu LG, Zhang RR, Xu RH: The effect of ventricular fibrillation time and NYHA classification on defibrillation in intensive care unit patients. Chin Crit Care Med 2013, 25(2):99–101.
21. Fox K, Boer J, Camm AJ, Danchin N, Ferrati R, Lopez Sendon JL, Steeg PG, Tariff JC, Tavazzi L, Tendera M: Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007, 50(9):823–830.
22. Lenis G, Dossel O: T Wave Morphology during Heart Rate Turbulence in Patients with Chronic Heart Failure. Biomed Tech (Berlin) 2013, 58(Suppl. 1):1.
23. Stein PK, Barzilay JI: Relationship of abnormal heart rate turbulence and elevated CRP to cardiac mortality in low, intermediate, and high-risk older adults. J Cardiovasc Electrophysiol 2011, 22(2):122–127.
24. Lonvihaya P, Addo K, Chadosh A, Iyer V, Lunn J, Buxton AE: Sudden cardiac death risk stratification in patients with heart failure. Heart Fail Clin 2011, 7(2):157–174, vi.
25. Bauer A, Bartheil P, Muller A, Ulm K, Hulskur H, Malik M, Schmidt G: Risk prediction by heart rate turbulence and deceleration capacity in postinfarction patients with preserved left ventricular function retrospective analysis of 4 independent trials. J Electrocardiol 2009, 42(6):597–601.
26. Cozzolino D, Furlan R, Guosso D, Maggio CD, Giudice EM, Torella R, Guagliardo D: Effects of a mixed meal on hemodynamics and autonomic control of the heart in patients with type 1 diabetes. J Clin Endocrinol Metabol 2010, 95(1):194–200.
27. Francis J, Watanabe MA, Schmidt G: Heart rate turbulence: a new predictor for risk of sudden cardiac death. Annals Noninvasive Electrocardiology 2005, 10(1):102–109.
28. Manzano-Fernandez S, Pastor-Perez FJ, Barquero-Perez O, Pascual-Figal DA, Goya-Esteban R, Rojo-Alvarez JL, Caamaño-Fernández A, Martinez-Martínez E, Espejo MD, Januzzi JL, Valdés M, García-Alberola A, Perez-Rodriguez A, Gonzalez-Segura D: Usefulness of abnormal heart rate turbulence for prediction of heart transplantation and mortality in chronic heart failure. Am J Cardiol 2011, 107(24):301–307.
29. Lewis MJ, Amadine J, D’Silva LA, Davies RE, Reed Z, Lewis KE: Influence of long-term oxygen therapy on cardiac acceleration and deceleration capacity in hypoxic patients with chronic obstructive pulmonary disease. Clin Physiol Funct Imaging 2011, 31(4):238–243.
30. Stein PK, Devarwania P: Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). Am J Cardiol 2009, 103(1):1495–1499.
31. Trzcins E, Krzeminska-Pakula M, Rechciński T, Drozdz J, Kurpesa M: Heart rate turbulence in patients with chronic heart failure. Kardiol Pol 2008, 66(1):1185–1190, discussion 1191–1183.
32. Piotrowicz E, Baranowski R, Piotrowska M, Zielinski T, Piotrowicz R: Variable effects of physical training of heart rate variability, heart rate recovery, and heart rate turbulence in chronic heart failure. Pacing Clin Electrophysiol 2009, 32(Suppl 1):S113–115.

33. Hadase M, Azuma A, Zen K, Asada S, Kawasaki T, Kamitani T, Kawasaki S, Sugihara H, Matsuura H: Very low frequency power of heart rate variability is a powerful predictor of clinical prognosis in patients with congestive heart failure. Circ J 2004, 68(4):343–347.

34. Kindermann M: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28(21):2686. author reply 2686–2687.

35. Fox K, Ferrari R, Tendera M, Steg PG, Ford I: Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morbidity-mortality Evaluation of the If inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study. Am Heart J 2006, 152(5):860–866.

36. Nul DR, Doval HC, Grancelli HO, Varini SD, Soffer S, Perrone SV, Pierto N, Scapin O: Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicentricos en Argentina. J Am Coll Cardiol 1997, 29(6):1199–1205.

doi:10.1186/1471-2261-14-50

Cite this article as: Yin et al.: Prognostic significance of heart rate turbulence parameters in patients with chronic heart failure. BMC Cardiovascular Disorders 2014 14:50.